瀚晖制药有限公司

Chinese pharmaceutical company formerly known as Hisun-Pfizer Pharmaceuticals, set up in 2012 as a joint venture between Zhejiang Hisun Pharmaceutical and Pfizer and now a wholly owned subsidiary of Hisun. Develops, manufactures and promotes high quality branded generics and off-patent originator medicines to international standards for the Chinese and global markets, supplying more than seventy products across oncology, anti-infectives, cardiovascular disease, diabetes, hormones and immunosuppressants. Its cGMP-compliant Fuyang production base, built with 1.5 billion yuan of investment, came on stream in May 2014.